Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019

Clinical Infectious Diseases - Tập 71 Số 12 - Trang 3232-3236 - 2020
Jianghong Fan1, Xinyuan Zhang1, Jiang Liu1, Yuching Yang1, Nan Zheng1, Qi Liu2, Kimberly L. Bergman2, Kellie S. Reynolds3, Shiew‐Mei Huang2, Hao Zhu1, Yaning Wang1
1Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
2Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
3Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA

Tóm tắt

Abstract Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.

Từ khóa


Tài liệu tham khảo

Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [manuscript published online ahead of print 9 March 2020], Clin Infect Dis, 10.1093/cid/ciaa237

Fu, 2014, Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering, Nat Chem, 6, 614, 10.1038/nchem.1961

Zhang, 2010, Cells on pores: a simulation-driven analysis of transcellular small molecule transport, Mol Pharm, 7, 456, 10.1021/mp9001969

Vincent, 2005, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, 2, 69, 10.1186/1743-422X-2-69

Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, 6, 16, 10.1038/s41421-020-0156-0

MacIntyre, 1993, Kinetics of chloroquine uptake into isolated rat hepatocytes, J Pharm Sci, 82, 592, 10.1002/jps.2600820610

Liu, 2003, Antimicrobial tissue concentrations, Infect Dis Clin North Am, 17, 599, 10.1016/S0891-5520(03)00060-6

Bergqvist, 1983, Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma, J Chromatogr, 272, 137, 10.1016/S0378-4347(00)86110-1

Tett, 1988, A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers, Br J Clin Pharmacol, 26, 303, 10.1111/j.1365-2125.1988.tb05281.x

Tett, 1989, Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Clin Pharmacol, 27, 771, 10.1111/j.1365-2125.1989.tb03439.x

Lim, 2009, Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax, Antimicrob Agents Chemother, 53, 1468, 10.1128/AAC.00339-08

Al-Kofahi, 2020, Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness [manuscript published online ahead of print 28 April 2020], Clin Pharmacol Ther, 10.1002/cpt.1874

Garcia-Cremades, 2020, Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing [manuscript published online ahead of print 14 April 2020], Clin Pharmacol Ther, 10.1002/cpt.1856

Cortegiani, 2020, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care, 57, 279, 10.1016/j.jcrc.2020.03.005

Singh, 2020, Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries, Diabetes Metab Syndr, 14, 241, 10.1016/j.dsx.2020.03.011

Arnold, 2020, Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection [manuscript published online ahead of print 8 April 2020], Clin Transl Sci, 10.1111/cts.12797

Kapoor, 2020, Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection—a systematic literature review, medRxiv

Tansan, 2020, A possible role for single dose hydroxychloroquine for prevention of lethal coronavirus infection, Özel Tansan Polikliniği

Guastalegname, 2020, Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?, Clin Infect Dis, 10.1093/cid/ciaa321

Vicente, 2019, Assessment of multi-ion channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study, Clin Pharmacol Ther, 105, 943, 10.1002/cpt.1303

Chorin, 2020, The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin, medRxiv [Preprint]. Posted 3 April

Thông tin
Thông tin xuất bản

Clinical Infectious Diseases

Tập 71 Số 12

3232-3236

Thông tin tác giả